CGT

830개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved830 programs
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Gastric Cancer, Metastatic · Lymphoid

#Lymphoid#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 4Status Recruiting
CGTLimited DatastaleSanofiPhase 1

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Active
CGTLimited DatastaleAllotera TherapeuticsPhase 1

WU-CART-007 (WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Active
CGTLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 1

anti-CD33 CAR NK cells (anti-CD33 CAR NK cells)

Leukemia, Myeloid, Acute · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Active
CGTLimited DatastaleTmunity Therapeutics, a wholly …Phase 1

huCART-meso cells (huCART-meso cells)

Pancreatic Cancer; Cancer of the Pancreas · Pancreatic Cancer

#PancreaticCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Discontinued
CGTLimited DatastaleXinqiao Hospital of ChongqingPhase 1

in vivo CAR-T drug based on LNP-mRNA (in vivo CAR-T drug based on LNP-mRNA)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 4Status Recruiting
CGTLimited DatastaleBeacon TherapeuticsPhase 2

rAAV2tYF-GRK1-RPGR (rAAV2tYF-GRK1-RPGR)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 4Status Recruiting
CGTAAVLimited DatastaleMeiraGTx UK II LtdPhase 2

AAV - CNGB3 (AAV - CNGB3)

Achromatopsia · Achromatopsia

#Achromatopsia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 3Status Active
CGTAAVLimited DatastaleLibella Gene TherapeuticsPhase 1

AAV-hTERT (AAV-hTERT)

Aging · Alzheimer Disease

#AlzheimerDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleThe First Affiliated Hospital o…Preclinical

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. (Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 2

Arlocabtagene Autoleucel (Arlocabtagene Autoleucel)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTStandard DatabasestaleJuno Therapeutics, Inc., a Bris…Phase 2

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleGenetix Biotherapeutics Inc.Phase 2

Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a (Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a)

Sickle Cell Disease · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

1.0 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^6 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

7.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 2

CAR-BCMA T Cells (CAR-BCMA T Cells)

Refractory or Relapsed Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleFondazione Matilde Tettamanti M…Phase 2

CARCIK-CD19 (CARCIK-CD19)

Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active

11 / 42 pages

← PreviousNext →